218 related articles for article (PubMed ID: 16766086)
1. PPARgamma as a therapeutic target in central nervous system diseases.
Sundararajan S; Jiang Q; Heneka M; Landreth G
Neurochem Int; 2006 Jul; 49(2):136-44. PubMed ID: 16766086
[TBL] [Abstract][Full Text] [Related]
2. Peroxisome proliferator-activated receptor gamma agonists as neuroprotective agents.
Kaundal RK; Sharma SS
Drug News Perspect; 2010 May; 23(4):241-56. PubMed ID: 20520853
[TBL] [Abstract][Full Text] [Related]
3. Drug insight: effects mediated by peroxisome proliferator-activated receptor-gamma in CNS disorders.
Heneka MT; Landreth GE; Hüll M
Nat Clin Pract Neurol; 2007 Sep; 3(9):496-504. PubMed ID: 17805244
[TBL] [Abstract][Full Text] [Related]
4. Peroxisome proliferator-activated receptor gamma agonists as therapy for chronic airway inflammation.
Belvisi MG; Hele DJ; Birrell MA
Eur J Pharmacol; 2006 Mar; 533(1-3):101-9. PubMed ID: 16458290
[TBL] [Abstract][Full Text] [Related]
5. Peroxisome proliferator-activated receptorsgamma (PPARgamma) differently modulate the interleukin-6 expression in the peri-infarct cortical tissue in the acute and delayed phases of cerebral ischaemia.
Patzer A; Zhao Y; Stöck I; Gohlke P; Herdegen T; Culman J
Eur J Neurosci; 2008 Nov; 28(9):1786-94. PubMed ID: 18973594
[TBL] [Abstract][Full Text] [Related]
6. The many faces of PPARgamma: anti-inflammatory by any means?
Szanto A; Nagy L
Immunobiology; 2008; 213(9-10):789-803. PubMed ID: 18926294
[TBL] [Abstract][Full Text] [Related]
7. The brain as a target for inflammatory processes and neuroprotective strategies.
Skaper SD
Ann N Y Acad Sci; 2007 Dec; 1122():23-34. PubMed ID: 18077562
[TBL] [Abstract][Full Text] [Related]
8. P2X7 receptor signaling pathway as a therapeutic target for neurodegenerative diseases.
Takenouchi T; Sekiyama K; Sekigawa A; Fujita M; Waragai M; Sugama S; Iwamaru Y; Kitani H; Hashimoto M
Arch Immunol Ther Exp (Warsz); 2010 Apr; 58(2):91-6. PubMed ID: 20143170
[TBL] [Abstract][Full Text] [Related]
9. Thiazolidinedione class of peroxisome proliferator-activated receptor gamma agonists prevents neuronal damage, motor dysfunction, myelin loss, neuropathic pain, and inflammation after spinal cord injury in adult rats.
Park SW; Yi JH; Miranpuri G; Satriotomo I; Bowen K; Resnick DK; Vemuganti R
J Pharmacol Exp Ther; 2007 Mar; 320(3):1002-12. PubMed ID: 17167171
[TBL] [Abstract][Full Text] [Related]
10. Cannabinoid system and neuroinflammation: implications for multiple sclerosis.
Correa F; Docagne F; Mestre L; Loría F; Hernangómez M; Borrell J; Guaza C
Neuroimmunomodulation; 2007; 14(3-4):182-7. PubMed ID: 18073512
[TBL] [Abstract][Full Text] [Related]
11. PPAR-gamma: therapeutic target for ischemic stroke.
Culman J; Zhao Y; Gohlke P; Herdegen T
Trends Pharmacol Sci; 2007 May; 28(5):244-9. PubMed ID: 17416424
[TBL] [Abstract][Full Text] [Related]
12. Peroxisome proliferator-activated receptor gamma agonist down-regulates IL-17 expression in a murine model of allergic airway inflammation.
Park SJ; Lee KS; Kim SR; Min KH; Choe YH; Moon H; Chae HJ; Yoo WH; Lee YC
J Immunol; 2009 Sep; 183(5):3259-67. PubMed ID: 19641141
[TBL] [Abstract][Full Text] [Related]
13. PPARs as new therapeutic targets for the treatment of cerebral ischemia/reperfusion injury.
Collino M; Patel NS; Thiemermann C
Ther Adv Cardiovasc Dis; 2008 Jun; 2(3):179-97. PubMed ID: 19124421
[TBL] [Abstract][Full Text] [Related]
14. Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications.
Touyz RM; Schiffrin EL
Vascul Pharmacol; 2006 Jul; 45(1):19-28. PubMed ID: 16782410
[TBL] [Abstract][Full Text] [Related]
15. Neuroprotective effects of prostaglandin A(1) in rat models of permanent focal cerebral ischemia are associated with nuclear factor-kappaB inhibition and peroxisome proliferator-activated receptor-gamma up-regulation.
Zhang HL; Gu ZL; Savitz SI; Han F; Fukunaga K; Qin ZH
J Neurosci Res; 2008 Apr; 86(5):1132-41. PubMed ID: 18074385
[TBL] [Abstract][Full Text] [Related]
16. Brain endothelial PPARgamma controls inflammation-induced CD4+ T cell adhesion and transmigration in vitro.
Klotz L; Diehl L; Dani I; Neumann H; von Oppen N; Dolf A; Endl E; Klockgether T; Engelhardt B; Knolle P
J Neuroimmunol; 2007 Oct; 190(1-2):34-43. PubMed ID: 17719655
[TBL] [Abstract][Full Text] [Related]
17. Peroxisome proliferator-activated receptor gamma (PPAR gamma) and sepsis.
von Knethen A; Soller M; Brüne B
Arch Immunol Ther Exp (Warsz); 2007; 55(1):19-25. PubMed ID: 17277894
[TBL] [Abstract][Full Text] [Related]
18. Combination therapy of rosiglitazone, a peroxisome proliferator-activated receptor-gamma ligand, and NMDA receptor antagonist (MK-801) on experimental embolic stroke in rats.
Allahtavakoli M; Shabanzadeh A; Roohbakhsh A; Pourshanazari A
Basic Clin Pharmacol Toxicol; 2007 Nov; 101(5):309-14. PubMed ID: 17910613
[TBL] [Abstract][Full Text] [Related]
19. [Anti-inflammatory effect of PPARgamma agonists: basics and clinical applications].
Wada K; Kamisaki Y
Nihon Rinsho; 2010 Feb; 68(2):278-83. PubMed ID: 20158097
[TBL] [Abstract][Full Text] [Related]
20. Peroxisome proliferator-activated receptor-gamma-mediated effects in the vasculature.
Duan SZ; Usher MG; Mortensen RM
Circ Res; 2008 Feb; 102(3):283-94. PubMed ID: 18276926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
